Dermira Inc (NASDAQ:DERM) Director David E. Cohen sold 600 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $28.03, for a total value of $16,818.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Dermira Inc (NASDAQ:DERM) traded down $0.63 during midday trading on Thursday, reaching $28.08. The company’s stock had a trading volume of 992,008 shares, compared to its average volume of 759,267. The company has a quick ratio of 4.68, a current ratio of 4.68 and a debt-to-equity ratio of 1.40. Dermira Inc has a 52 week low of $21.35 and a 52 week high of $38.75. The company has a market capitalization of $1,136.04, a PE ratio of -4.51 and a beta of 0.80.
A number of research firms recently commented on DERM. BidaskClub upgraded Dermira from a “hold” rating to a “buy” rating in a research report on Wednesday, December 20th. Guggenheim reissued a “buy” rating and set a $30.00 price objective on shares of Dermira in a research note on Thursday, December 14th. Mizuho reduced their price objective on Dermira from $43.00 to $39.00 and set a “buy” rating on the stock in a research note on Tuesday, December 12th. Cantor Fitzgerald set a $45.00 price objective on Dermira and gave the stock a “buy” rating in a research note on Wednesday, November 29th. Finally, Zacks Investment Research cut Dermira from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Three equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. Dermira has a consensus rating of “Hold” and an average target price of $41.00.
TRADEMARK VIOLATION NOTICE: “David E. Cohen Sells 600 Shares of Dermira Inc (DERM) Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/04/david-e-cohen-sells-600-shares-of-dermira-inc-derm-stock.html.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.